• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Centogene N.V. (Amendment)

    2/22/22 4:00:59 PM ET
    $CNTG
    Medical Specialities
    Health Care
    Get the next $CNTG alert in real time by email
    SC 13D/A 1 d311511dsc13da.htm SC 13D/A SC 13D/A

     

     

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13D/A

    Under the Securities Exchange Act of 1934

    (Amendment No. 4)*

     

     

    Centogene N.V.

    (Name of Issuer)

    Common Shares, €0.12 par value per share

    (Title of Class of Securities)

    N1976T109

    (CUSIP Number)

    Florian Kaiser

    DPE Deutsche Private Equity

    Ludwigstrasse 7

    80539 Munich, Germany

    +49 89 200038-0

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

    January 31, 2022

    (Date of Event Which Requires Filing of this Statement)

     

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.  ☐

     

     

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Section 240.13d-7 for other parties to whom copies are to be sent.

     

     

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. N1976T109

     

      1.    

       Names of Reporting Persons.

     

      DPE Deutsche Private Equity Gesellschaft mbH

      2.  

      Check the Appropriate Box if a Member of a Group (See Instructions)

      (a)  ☐        (b)  ☒

     

      3.  

      SEC Use Only

     

      4.  

      Source of Funds (See Instructions)

     

      WC

      5.  

      Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

     

      ☐

      6.  

      Citizenship or Place of Organization

     

      Germany

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

     

         7.    

      Sole Voting Power

     

      0

         8.  

      Shared Voting Power

     

      8,241,315

         9.  

      Sole Dispositive Power

     

      0

       10.  

      Shared Dispositive Power

     

      8,241,315

    11.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      8,241,315

    12.  

      Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

     

      ☐

    13.  

      Percent of Class Represented by Amount in Row (11)

     

      29.9%

    14.  

      Type of Reporting Person (See Instructions)

     

      OO


    CUSIP No. N1976T109

     

      1.    

       Names of Reporting Persons.

     

      DPE Deutschland II A GmbH & Co. KG

      2.  

      Check the Appropriate Box if a Member of a Group (See Instructions)

      (a)  ☐        (b)  ☒

     

      3.  

      SEC Use Only

     

      4.  

      Source of Funds (See Instructions)

     

      WC

      5.  

      Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

     

      ☐

      6.  

      Citizenship or Place of Organization

     

      Germany

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

     

         7.    

      Sole Voting Power

     

      0

         8.  

      Shared Voting Power

     

      5,415,661

         9.  

      Sole Dispositive Power

     

      0

       10.  

      Shared Dispositive Power

     

      5,415,661

    11.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      5,415,661

    12.  

      Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

     

      ☐

    13.  

      Percent of Class Represented by Amount in Row (11)

     

      19.8%

    14.  

      Type of Reporting Person (See Instructions)

     

      OO


    CUSIP No. N1976T109

     

      1.    

       Names of Reporting Persons.

     

      DPE Deutschland II B GmbH & Co. KG

      2.  

      Check the Appropriate Box if a Member of a Group (See Instructions)

      (a)  ☐        (b)  ☒

     

      3.  

      SEC Use Only

     

      4.  

      Source of Funds (See Instructions)

     

      WC

      5.  

      Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

     

      ☐

      6.  

      Citizenship or Place of Organization

     

      Germany

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

     

         7.    

      Sole Voting Power

     

      0

         8.  

      Shared Voting Power

     

      2,825,654

         9.  

      Sole Dispositive Power

     

      0

       10.  

      Shared Dispositive Power

     

      2,825,654

    11.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      2,825,654

    12.  

      Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

     

      ☐

    13.  

      Percent of Class Represented by Amount in Row (11)

     

      10.4%

    14.  

      Type of Reporting Person (See Instructions)

     

      OO


    CUSIP No. N1976T109

     

      1.    

       Names of Reporting Persons.

     

      Deutsche Private Equity Administration GmbH

      2.  

      Check the Appropriate Box if a Member of a Group (See Instructions)

      (a)  ☐        (b)  ☒

     

      3.  

      SEC Use Only

     

      4.  

      Source of Funds (See Instructions)

     

      WC

      5.  

      Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

     

      ☐

      6.  

      Citizenship or Place of Organization

     

      Germany

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

     

         7.    

      Sole Voting Power

     

      0

         8.  

      Shared Voting Power

     

      8,241,315

         9.  

      Sole Dispositive Power

     

      0

       10.  

      Shared Dispositive Power

     

      8,241,315

    11.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      8,241,315

    12.  

      Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

     

      ☐

    13.  

      Percent of Class Represented by Amount in Row (11)

     

      29.9%

    14.  

      Type of Reporting Person (See Instructions)

     

      OO


    CUSIP No. N1976T109

     

      1.    

       Names of Reporting Persons.

     

      Marc Thiery

      2.  

      Check the Appropriate Box if a Member of a Group (See Instructions)

      (a)  ☐        (b)  ☒

     

      3.  

      SEC Use Only

     

      4.  

      Source of Funds (See Instructions)

     

      WC

      5.  

      Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

     

      ☐

      6.  

      Citizenship or Place of Organization

     

      Germany

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

     

         7.    

      Sole Voting Power

     

      0

         8.  

      Shared Voting Power

     

      8,241,315

         9.  

      Sole Dispositive Power

     

      0

       10.  

      Shared Dispositive Power

     

      8,241,315

    11.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      8,241,315

    12.  

      Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

     

      ☐

    13.  

      Percent of Class Represented by Amount in Row (11)

     

      29.9%

    14.  

      Type of Reporting Person (See Instructions)

     

      IN


    Explanatory Note

    This Amendment No. 4 (this “Amendment”) amends and supplements the Schedule 13D filed with the Securities and Exchange Commission on November 22, 2019 by the Reporting Persons (as amended from time to time, the “Schedule 13D”), relating to their beneficial ownership in Centogene N.V. (the “Issuer”). Except to the extent set forth in this Amendment, all material information disclosed in the Schedule 13D remains unchanged. Capitalized terms used but not defined in this Amendment have the respective meanings set forth in the Schedule 13D.

     

    Item 3.

    Source and Amount of Funds or Other Consideration

    Item 3 of the Schedule 13D is hereby amended and supplemented as follows:

    DPE II A and DPE II B purchased the securities set forth in Item 5 using funds from working capital.

     

    Item 5.

    Interest in Securities of the Issuer

    Item 5 of the Schedule 13D is hereby amended as follows:

    (a)-(b) The information set forth in rows 7 through 13 of the cover pages to this Schedule 13D is incorporated by reference. The percentage set forth in row 13 is based on 27,071,224 outstanding shares of Common Stock, as reported by the Issuer to the Reporting Persons, and includes the Warrants set forth in Item 5(c) below.

    (c) On January 31, 2022 DPE II A acquired 1,098,798 shares of Common Stock and warrants to purchase 329,639 shares of Common Stock (“Warrants”) and DPE II B acquired 573,395 shares of Common Stock and Warrants to acquire 172,018 shares of Common Stock from the Issuer at a purchase price of $3.73 per share from the Issuer in its private placement financing. The Warrants are exercisable at an exercise price of $7.72 per share at an exercise price of $7.72 per share and expire December 31, 2026.

     

    Item 6.

    Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer

    Item 6 of the Schedule 13D is hereby amended and supplemented as follows:

    The information set forth in Item 5(c) above is incorporated by reference into this Item 6.

    The securities set forth in Item 5(c) were acquired pursuant to a Securities Purchase Agreement, a copy of which is filed as Exhibit 4 to this Schedule 13D and is incorporated by reference into this Item 6.

     

    Item 7.

    Material to be Filed as Exhibits

    Item 7 of the Schedule 13D is hereby amended and supplemented as follows:

    Exhibit 4 Securities Purchase Agreement, dated January 31, 2022, by and among Centogene N.V. and the Investors identified on Schedule 1 attached thereto (incorporated by reference to Exhibit 99.4 to the Issuer’s Form 6-K furnished with the SEC on February 1, 2022) (the Issuer has omitted portions of this exhibit pursuant to Item 601(b)(10)(iv) of Regulation S-K on the basis that the Company customarily and actually treats that information as private or confidential and the omitted information is not material)

    Exhibit 5 Warrant Agreement, dated January 31, 2022, by and among Centogene N.V. and the Investors identified on Schedule 1 attached thereto (incorporated by reference to Exhibit 99.5 to the Issuer’s Form 6-K furnished with the SEC on February 1, 2022)


    SIGNATURES

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated: February 22, 2022

     

    DPE DEUTSCHE PRIVATE EQUITY GESELLSCHAFT MBH
    By:  

    /s/ Marc Thiery

    Name:   Marc Thiery
    Title:   Managing Director
    DPE DEUTSCHLAND II A GMBH & CO. KG
    By its general partner Deutsche Private Equity Administration GmbH
    By:  

    /s/ Marc Thiery

    Name:   Marc Thiery
    Title:   Managing Director
    DPE DEUTSCHLAND II B GMBH & CO. KG
    By its general partner Deutsche Private Equity Administration GmbH
    By:  

    /s/ Marc Thiery

    Name:   Marc Thiery
    Title:   Managing Director
    DEUTSCHE PRIVATE EQUITY ADMINISTRATION GMBH
    By:  

    /s/ Marc Thiery

    Name:   Marc Thiery
    Title:   Managing Director

    /s/ Marc Thiery

    Marc Thiery
    Get the next $CNTG alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CNTG

    DatePrice TargetRatingAnalyst
    8/5/2021$14.00Outperform
    Credit Suisse
    More analyst ratings

    $CNTG
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • CENTOGENE Closes Strategic Transaction with Private Equity Group Charme Capital Partners

      CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, March 12, 2025 (GLOBE NEWSWIRE) -- Centogene N.V. (OTC:CNTGF) ("CENTOGENE" or the "Company") today announced it has closed its transaction to sell its operating subsidiaries to an affiliate of Charme Capital Partners Limited ("Charme"). As announced on November 13, 2024, the Company had entered into definitive agreements with Charme for the sale of 100% ownership in Centogene GmbH, CENTOGENE's sole operating subsidiary, certain intercompany receivables, and assumption of the Company's loan granted by Oxford Finance LLC (the "Transaction"). On December 4, 2024, the Company held an Extraordinary General Meeting ("EGM") in connection with th

      3/12/25 6:30:00 AM ET
      $CNTG
      Medical Specialities
      Health Care
    • CENTOGENE Announces Voting Results of Extraordinary General Meeting

      CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Centogene N.V. (OTC:CNTGF) ("CENTOGENE" or the "Company"), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced the voting results of the Company's Extraordinary General Meeting. Shareholders voted in favor of all proposals, which included the approval of the previously announced envisaged sale and transfer of Centogene GmbH to Charme Capital Partners Limited, a pan-European private equity firm. At the Extraordinary General Meeting of CENTOGENE, 57.16% of the Company's issued share capital were represented. About CENTOGENE CENTOGENE's mi

      12/4/24 7:51:01 PM ET
      $CNTG
      Medical Specialities
      Health Care
    • CENTOGENE Signs Strategic Transaction With Private Equity Group Charme Capital Partners

      CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Centogene N.V. (OTC:CNTGF) ("CENTOGENE" or the "Company"), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced it has concluded its strategic review process and has entered into a Share Purchase Agreement ("SPA") pursuant to which its operating subsidiaries will be sold to an affiliate of Charme Capital Partners Limited ("Charme"), a pan-European private equity firm, for a cash purchase price of EUR 8,717,906.80. In connection with the transaction, Centogene GmbH will receive funding, secured by Saudi accounts receivables, from its Saudi Arabian

      11/13/24 6:30:01 AM ET
      $CNTG
      Medical Specialities
      Health Care

    $CNTG
    Leadership Updates

    Live Leadership Updates

    See more
    • CENTOGENE Reports First Half 2023 Financial Results

      First half 2023 total revenues with double-digit growth of 15.1% at €24.6 millionBoth Pharma and Diagnostics segments deliver strong performance, reaffirming full year 2023 guidance for total revenue growth between 10% to 15%Recently announced strategic collaboration with Lifera, a biopharmaceutical company wholly-owned by the Saudi Arabia Public Investment Fund (PIF), strengthens global genomic and multiomic footprint and secures CENTOGENE $30 million investment and approx. $50 million in Joint Venture upfront payment and performance-related milestones CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Centogene N.V. (NASDAQ:CNTG), the essential life s

      9/7/23 5:00:52 PM ET
      $CNTG
      Medical Specialities
      Health Care
    • CENTOGENE Announces Approval of All Resolutions Tabled at 2023 Annual General Meeting

      CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, June 30, 2023 (GLOBE NEWSWIRE) -- CENTOGENE N.V. (NASDAQ:CNTG) (the "Company"), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced the voting results of the Company's Annual General Meeting. Shareholders voted in favor of all proposals, which included the appointment of Prof. Dr. Peter Bauer as a member of the Management Board of the Company, as well as the appointment of Mary Sheahan and the reappointment of Peer Schatz as members of the Supervisory Board of the Company. The shareholders extended the period for drawing up the Dutch statutory annual accounts and board report f

      6/30/23 4:30:02 PM ET
      $CNTG
      Medical Specialities
      Health Care
    • CENTOGENE Reports Full Year 2022 Financial Results

      Full Year 2022 total revenues with double-digit growth of 12% at €47.5 million, in line with prior guidanceSignificant expansion of gross profit margin from 32% to 42% and ongoing cost control resulted in significant improvement of net resultsBoth Pharma and Diagnostics segments positioned for strong performance in 2023, guidance of FY2023 total revenue growth between 10% to 15% CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, May 16, 2023 (GLOBE NEWSWIRE) -- Centogene N.V. (NASDAQ:CNTG) ("we" or the "Company"), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced financial results for the fiscal year ended December 31, 2022,

      5/16/23 6:25:08 PM ET
      $CNTG
      Medical Specialities
      Health Care

    $CNTG
    Financials

    Live finance-specific insights

    See more
    • CENTOGENE Reports Fourth Quarter and Full Year 2021 Financial Results

      - Full Year 2021 Total Revenue Growth of 48%, and 11% in Core Business Segments, Exceeds Guidance - Focus on Pharma and Diagnostics to Position for Strong Performance in 2022 - Closed $62 Million Financing Round and on Track to Exit COVID-19 Business - Management to Host Conference Call at 2 p.m. CET/8 a.m. ET Today CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, March 30, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (NASDAQ:CNTG), a commercial-stage company focused on generating data-driven insights to diagnose, understand, and treat rare diseases, today announced financial results for the fourth quarter and fiscal year ended December 31, 2021, and provided a business update. "2021 wa

      3/30/22 7:30:00 AM ET
      $CNTG
      Medical Specialities
      Health Care
    • CENTOGENE to Announce Fourth Quarter and Fiscal Year 2021 Financial Results on March 30, 2022

      CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, March 23, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (NASDAQ:CNTG), a commercial-stage company focused on generating data-driven insights to diagnose, understand, and treat rare diseases, today announced that it will issue its financial results for the quarter and full year ended December 31, 2021, on Wednesday, March 30, 2022, and will host a conference call and webcast to discuss these results at 2 p.m. CEST / 8 a.m. EDT that day. Participants may register in advance for the conference call and webcast to be held on March 30, 2022, at http://emea.directeventreg.com/registration/5737758. Upon registering, each participant will be provided w

      3/23/22 6:30:00 AM ET
      $CNTG
      Medical Specialities
      Health Care
    • CENTOGENE Reports Third Quarter 2021 Financial Results

      CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Nov. 24, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (NASDAQ:CNTG), a commercial-stage company focused on generating data-driven insights to diagnose, understand, and treat rare diseases, today announced financial results for the third quarter ended September 30, 2021, and provided a recent business update. Executive Commentary "We are encouraged by the progress achieved in Q3 on our continued path to return focus and growth to our rare disease business, driving strategic Core Business execution," stated Andrin Oswald, M.D., Chief Executive Officer at CENTOGENE. "We saw continued recovery trends in the Diagnostics segment, with over 40% incre

      11/24/21 7:35:47 AM ET
      $CNTG
      Medical Specialities
      Health Care

    $CNTG
    SEC Filings

    See more
    • SEC Form 6-K filed by Centogene N.V.

      6-K - Centogene N.V. (0001757097) (Filer)

      8/19/24 7:37:31 PM ET
      $CNTG
      Medical Specialities
      Health Care
    • SEC Form 6-K filed by Centogene N.V.

      6-K - Centogene N.V. (0001757097) (Filer)

      8/7/24 6:18:25 PM ET
      $CNTG
      Medical Specialities
      Health Care
    • SEC Form 6-K filed by Centogene N.V.

      6-K - Centogene N.V. (0001757097) (Filer)

      8/1/24 4:15:59 PM ET
      $CNTG
      Medical Specialities
      Health Care

    $CNTG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Centogene N.V. (Amendment)

      SC 13D/A - Centogene N.V. (0001757097) (Subject)

      3/11/22 4:44:52 PM ET
      $CNTG
      Medical Specialities
      Health Care
    • SEC Form SC 13D/A filed by Centogene N.V. (Amendment)

      SC 13D/A - Centogene N.V. (0001757097) (Subject)

      2/22/22 4:00:59 PM ET
      $CNTG
      Medical Specialities
      Health Care
    • SEC Form SC 13G filed by Centogene N.V.

      SC 13G - Centogene N.V. (0001757097) (Subject)

      12/8/21 8:52:19 PM ET
      $CNTG
      Medical Specialities
      Health Care

    $CNTG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Credit Suisse resumed coverage on Centogene with a new price target

      Credit Suisse resumed coverage of Centogene with a rating of Outperform and set a new price target of $14.00

      8/5/21 6:17:32 AM ET
      $CNTG
      Medical Specialities
      Health Care
    • Credit Suisse reiterated coverage on Centogene with a new price target

      Credit Suisse reiterated coverage of Centogene with a rating of Outperform and set a new price target of $14.00 from $15.00 previously

      6/17/21 7:44:42 AM ET
      $CNTG
      Medical Specialities
      Health Care